Core Viewpoint - The legal opinion letter from Guangdong Xinda Law Firm confirms that Shenzhen Meihua Chuangyi Medical Technology Co., Ltd. has obtained the necessary approvals and fulfilled disclosure obligations for its 2025 restricted stock incentive plan adjustments and initial grants [1][10]. Group 1: Approval and Authorization - The company submitted the draft of the 2025 restricted stock incentive plan to the board for review and approval [4]. - The board approved the adjustment of the initial grant list due to one participant's resignation, reducing the number of recipients from 304 to 303 while maintaining the total stock grant of 4.0129 million shares [6][7]. Group 2: Grant Details - The grant date for the initial stock award is set for May 23, 2025, following the approval from the shareholders' meeting [6][7]. - A total of 4.0129 million shares will be granted to 303 eligible participants at a price of 13.39 yuan per share [7][9]. Group 3: Compliance with Regulations - The adjustments and grants comply with relevant laws, regulations, and the company's internal guidelines, including the Management Measures and Listing Rules [6][10]. - The company has confirmed that all grant conditions have been met, ensuring that no disqualifying circumstances exist for the participants [9][10].
美好医疗: 广东信达律师事务所关于公司2025年限制性股票激励计划调整及首次授予事项的法律意见书